Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (757)	12/10/2007 2:59:32 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

I always liked INGN-241 <g> As Paul Fisher stated in 2005: Is mda-7/IL-24 a "Magic Bullet" for Cancer? Cancer Research 65, 10128-10138, November 15, 2005 "A specific gene, melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24), displaying cancer-specific apoptosis-inducing properties isolated using this scheme has now come into the limelight as a new gene therapy for divergent cancers. Although the mechanism of cancer cell selectivity of mda-7/IL-24 remains to be delineated, numerous attributes enable this gene as an effective therapy for cancer, including an ability to discriminate between normal and cancer cells, induce apoptosis in diverse tumor cells,inhibit tumor growth and angiogenesis in animal models, synergize with radiation, and modulate immune responses. These unique features combined with successful transition into the clinic instill confidence that mda-7/IL-24, as a single or more likely as part of a combinatorial approach, may provide profound therapeutic benefit for cancer patients". 17-AAG is less toxic & more stable than Geldanamycin,& although its binding to Hsp90 is weaker,it displays similar antitumor effects as Geldanamycin & has a better toxicity profile. Some of the preliminary data have shown that its antitumor activity can be achieved below its maximum tolerated dose. Advexin now seems to have good probabilities of been accepted in Europe. On Nov. 27,INGN & its subsidiary, Gendux, announced the advancement of a MAA for ADVEXIN, which has now been accepted for technical review by the EMEA for the treatment of LFS. This acceptance indicates that all administrative issues have been addressed and that the formal technical evaluation of the Application will be conducted under the EMEA's Exceptional Circumstances Approval rules. If approved, ADVEXIN would be the world's first treatment specific for an inherited cancer syndrome. ADVEXIN is targeted to reverse one of the most common cancer genetic defects that is inherited in Li-Fraumeni patients and found in the majority of non-inherited cancers. The acceptance of the MAA for ADVEXIN will initiate the regulatory review of the Application's preclinical, manufacturing and clinical data by EMEA. Exceptional Circumstances Approval rules available in Europe are being utilized by Gendux to expedite review of potential breakthrough therapies. The review will be based on clinical efficacy and safety results from the use of ADVEXIN in LFS and in a wide variety of non-inherited cancers with abnormal p53 tumor suppression that is the target of ADVEXIN treatment. Abnormal p53 is inherited in LFS and is also the most commonly identified defective gene in all solid cancers whether inherited or acquired. Patients' tumors can be checked to determine if they have the p53 abnormality targeted by ADVEXIN using widely available tests. Dr. Max Talbott,INGN's senior V.P. of Worldwide Regulatory Affairs said, "The ADVEXIN application is a historic submission, and could represent a truly personalized cancer therapy approach. We are encouraged by the EMEA's acceptance of our Application under the Exceptional Circumstances Approval provisions and now look forward to working with the European regulatory authorities during the technical review process." But I still like INGN-241 > Advexin.<g> RAGL Bernard